The Hidden Variable

Why aligner brands take the blame for clinical decisions they don't control.

A 45-minute conversation with Sheldon Krancher, co-founder and managing partner of ClearForward. We'll look at one of the biggest hidden risks in clear aligner therapy: how treatment planning quality shapes brand reputation. The business impact is bigger than most brands realise.

Free to attend. We'll send the replay and the research white paper to everyone who registers.

Why this matters

The question most aligner brands haven't asked yet.

Clear aligner therapy uses precision tech and digital tools. But the biggest factor in whether a case succeeds is the quality of the treatment plan made before the first aligner is produced. More important than the material, the manufacturing, or the brand itself.

Aligner tooth movement is only 41 to 73 percent accurate. 70 to 80 percent of cases need at least one refinement. Only six percent of patients finish treatment without any refinement at all. Planning quality is what drives these numbers.

The problem this creates for aligner brands is bigger than most brand teams have noticed. Patients don't understand treatment planning. They don't see the staging, the attachments, or the order of movements. They see the brand on the box. So when results disappoint, they blame the brand. The clinical decisions came from somewhere else.

"Treatment planning is invisible to the patient. The brand stays visible. When planning fails, the brand takes the blame."

What you'll leave with

Three things, by the end of the 45 minutes.

A framework you can use

A simple model we call the Brand Attribution Gap. It helps you separate product risk from planning risk across your provider network.

The four planning choices that predict complaints

The four planning decisions that most often decide whether a case tracks to plan or ends in a one-star review. Based on peer-reviewed research and 600,000 treatment plans of our own data.

How clinical oversight works at scale

Three real-world ways aligner brands and dental groups build clinical oversight. We'll cover cost, what scales, and where each model breaks down.

Who this is for.

This session is for people responsible for the business results of clinical work. Specifically:

Aligner brand executives, founders, and clinical or commercial leaders. If your brand is on the box and a patient's review is on Google, this is for you.
DSO and multi-location group leaders, especially clinical directors managing aligner cases across locations where refinement rates vary in ways your operations team sees but your marketing team feels.
Dental lab and OEM leaders building or supporting aligner programmes.

Your host

Sheldon Krancher

Co-founder and Managing Partner · ClearForward

Sheldon is a serial healthcare entrepreneur and co-founder of ClearForward. For more than fifteen years, he has built ClearForward into the clinical layer behind aligner brands, dental labs, and multi-location dental groups in over fifty countries. Together with the team, he has delivered over 600,000 treatment plans to 30,000 providers worldwide and helped develop the Treatment Plan Optimization™ (TPO) methodology used across the industry.

The practical details.

Date: Tuesday 15 July 2026
Time: 18:00 CET; 17:00 BST · 12:00 EDT
Duration: 45 minutes; Including live Q&A
Language: English; Recording captioned post-event

Free to attend.

Can't make it live? Register anyway. We'll send the replay and the full research white paper. Same for everyone, whether you attend live or not.

Save your seat.

45 minutes with Sheldon Krancher on Tuesday 15 July at 18:00 CET. Free. We'll send the replay and the white paper to everyone who registers.